Associations between skeletal muscle strength and chronic kidney disease in patients with MASLD
Feng, G. et al. Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 21, 46–56 (2024).
Younossi, Z. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 15, 11–20 (2018).
Google Scholar
Rinella, M. E. et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79, 1542–1556 (2023).
Byrne, C. D. & Targher, G. MASLD, MAFLD, or NAFLD criteria: have we re-created the confusion and acrimony surrounding metabolic syndrome? Metab. Target Organ Damage 4, 10 (2024).
Google Scholar
Byrne, C. D. & Targher, G. NAFLD: a multisystem disease. J. Hepatol. 62, S47–S64 (2015).
Google Scholar
Wang, T. Y. et al. Association of metabolic dysfunction-associated fatty liver disease with kidney disease. Nat. Rev. Nephrol. 18, 259–268 (2022).
Google Scholar
Zhou, X. D. et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatol. Int. 17, 773–791 (2023).
Google Scholar
Sun, D. Q. et al. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease. Hepatobiliary Surg. Nutr. 12, 386–403 (2023).
Google Scholar
Sun, D. Q. et al. MAFLD and risk of CKD. Metabolism 115, 154433 (2021).
Google Scholar
Lonardo, A., Mantovani, A., Targher, G. & Baffy, G. Nonalcoholic fatty liver disease and chronic kidney disease: epidemiology, pathogenesis, and clinical and research implications. Int. J. Mol. Sci. 23, 13320 (2022).
Cruz-Jentoft, A. J. & Sayer, A. A. Sarcopenia. Lancet 393, 2636–2646 (2019).
Google Scholar
Seo, D. H. et al. Effect of low skeletal muscle mass and sarcopenic obesity on chronic kidney disease in patients with type 2 diabetes. Obesity (Silver Spring) 30, 2034–2043 (2022).
Google Scholar
Lopez-Lopez, J. P. et al. The prediction of Metabolic Syndrome alterations is improved by combining waist circumference and handgrip strength measurements compared to either alone. Cardiovasc. Diabetol. 20, 68 (2021).
Google Scholar
Kang, S., Moon, M. K., Kim, W. & Koo, B. K. Association between muscle strength and advanced fibrosis in non-alcoholic fatty liver disease: a Korean nationwide survey. J. Cachexia Sarcopenia Muscle 11, 1232–1241 (2020).
Google Scholar
Petermann-Rocha, F. et al. Associations of muscle mass and grip strength with severe NAFLD: a prospective study of 333,295 UK Biobank participants. J. Hepatol. 76, 1021–1029 (2022).
Google Scholar
Tang, L. J. et al. N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD. Hepatol. Int. 17, 190–201 (2023).
Google Scholar
Ha, S., Wong, V. W., Zhang, X. & Yu, J. Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma. Gut 74, 141–152 (2024).
Google Scholar
Perazzo, H., Pacheco, A. G. & Griep, R. H. Changing from NAFLD through MAFLD to MASLD: Similar prevalence and risk factors in a large Brazilian cohort. J. Hepatol. 80, e72–e74 (2024).
Google Scholar
Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313–1321 (2005).
Google Scholar
Mey, R. et al. Handgrip strength and respiratory disease mortality: Longitudinal analyses from SHARE. Pulmonology 30, 445–451 (2022).
Charatcharoenwitthaya, P., Karaketklang, K. & Aekplakorn, W. Muscle strength, but not body mass index, is associated with mortality in patients with non-alcoholic fatty liver disease. J. Cachexia Sarcopenia Muscle 13, 2393–2404 (2022).
Google Scholar
Ho, F. K. W. et al. The association of grip strength with health outcomes does not differ if grip strength is used in absolute or relative terms: a prospective cohort study. Age Ageing 48, 684–691 (2019).
Google Scholar
Inker, L. A. & Titan, S. Measurement and estimation of GFR for use in clinical practice: Core Curriculum 2021. Am. J. Kidney Dis. 78, 736–749 (2021).
Google Scholar
Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604–612 (2009).
Google Scholar
Delgado, C., Powe, N. R., Chertow, G. M., Grimes, B. & Johansen, K. L. Muscle mass and serum creatinine concentration by race and ethnicity among hemodialysis patients. J. Am. Soc. Nephrol. 35, 66–73 (2024).
Google Scholar
Peng, T. C. Role of Sarcopenia in nonalcoholic fatty liver disease: definition is crucially important. Hepatology 68, 788–789 (2018).
Google Scholar
Cho, J., Johnson, B. D., Watt, K. D. & Kim, C. H. Greater muscular strength is associated with a lower risk of pulmonary dysfunction in individuals with non-alcoholic fatty liver disease. J. Clin. Med. 11 (2022).
Avin, K. G. & Moorthi, R. N. Bone is not alone: the effects of skeletal muscle dysfunction in chronic kidney disease. Curr. Osteoporos. Rep. 13, 173–179 (2015).
Google Scholar
He, P. et al. Association of handgrip strength and/or walking pace with incident chronic kidney disease: A UK biobank observational study. J. Cachexia Sarcopenia Muscle 14, 805–814 (2023).
Google Scholar
Wang, X. H., Mitch, W. E. & Price, S. R. Pathophysiological mechanisms leading to muscle loss in chronic kidney disease. Nat. Rev. Nephrol. 18, 138–152 (2022).
Google Scholar
Hara, A. et al. Relationship between handgrip strength and albuminuria in community-dwelling elderly Japanese subjects: the Shika Study. Biomarkers 25, 587–593 (2020).
Google Scholar
Ye, C. et al. Causal associations of sarcopenia-related traits with cardiometabolic disease and Alzheimer’s disease and the mediating role of insulin resistance: a Mendelian randomization study. Aging Cell 22, e13923 (2023).
DeFronzo, R. A. & Tripathy, D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diab. Care 32, S157–S163 (2009).
Google Scholar
Zhou, J. et al. Metabolic dysfunction-associated fatty liver disease increases risk of chronic kidney disease: a systematic review and meta-analysis. eGastroenterology 1, e100005 (2023).
Google Scholar
Musso, G. et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 11, e1001680 (2014).
Google Scholar
Distefano, G. & Goodpaster, B. H. Effects of exercise and aging on skeletal muscle. Cold Spring Harb. Perspect. Med. 8 (2018).
Berzigotti, A., Saran, U. & Dufour, J. F. Physical activity and liver diseases. Hepatology 63, 1026–1040 (2016).
Google Scholar
Henry, A. et al. Vigorous physical activity provides protection against all-cause deaths among adults patients with nonalcoholic fatty liver disease (NAFLD). Aliment Pharm. Ther. 57, 709–722 (2023).
Google Scholar
Noor, H., Reid, J. & Slee, A. Resistance exercise and nutritional interventions for augmenting sarcopenia outcomes in chronic kidney disease: a narrative review. J. Cachexia Sarcopenia Muscle 12, 1621–1640 (2021).
Google Scholar
Heiwe, S. & Jacobson, S. H. Exercise training in adults with CKD: a systematic review and meta-analysis. Am. J. Kidney Dis. 64, 383–393 (2014).
Google Scholar
Zhang, X. L., Wang, T. Y., Targher, G., Byrne, C. D. & Zheng, M. H. Lifestyle interventions for non-obese patients both with, and at risk, of non-alcoholic fatty liver disease. Diab. Metab. J. 46, 391–401 (2022).
Google Scholar
Li, T., Hu, Z., Qiao, L., Wu, Y. & Ye, T. Chronic kidney disease and cognitive performance: NHANES 2011-2014. BMC Geriatr. 24, 351 (2024).
Google Scholar
Cusick, M. M., Tisdale, R. L., Chertow, G. M., Owens, D. K. & Goldhaber-Fiebert, J. D. Population-wide screening for chronic kidney disease: a cost-effectiveness analysis. Ann. Intern. Med. 176, 788–797 (2023).
Google Scholar
Fyfe, J. J., Hamilton, D. L. & Daly, R. M. Minimal-dose resistance training for improving muscle mass, strength, and function: a narrative review of current evidence and practical considerations. Sports Med. 52, 463–479 (2022).
Google Scholar
link
